CGEM Cullinan Oncology Inc
Price (delayed)
$8.71
Market cap
$509.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.78
Enterprise value
$428.79M
Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build
Highlights
The debt has declined by 40% year-on-year and by 12% since the previous quarter
Cullinan Oncology's equity has increased by 30% YoY but it has decreased by 6% from the previous quarter
The EPS is down by 18% since the previous quarter but it is up by 13% year-on-year
CGEM's quick ratio is down by 45% from the previous quarter and by 22% YoY
CGEM's net income is down by 17% from the previous quarter and by 9% YoY
Key stats
What are the main financial stats of CGEM
Market
Valuations
Earnings
Shares outstanding
58.51M
Market cap
$509.65M
Enterprise value
$428.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.86
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$196.92M
Net income
-$167.38M
EBIT
-$167.27M
EBITDA
-$166.96M
Free cash flow
-$145.3M
Per share
Balance sheet
Liquidity
EPS
-$2.78
EPS diluted
-$2.78
Free cash flow per share
-$2.7
Book value per share
$10.14
Revenue per share
$0
TBVPS
$11.56
Total assets
$621.82M
Total liabilities
$31.5M
Debt
$2.15M
Equity
$590.33M
Working capital
$384.02M
Debt to equity
0
Current ratio
13.53
Quick ratio
13.02
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.9%
Return on equity
-29.2%
Return on invested capital
-34.5%
Return on capital employed
-28.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CGEM stock price
How has the Cullinan Oncology stock price performed over time
Intraday
2.35%
1 week
2.59%
1 month
-14.69%
1 year
-46.73%
YTD
-28.49%
QTD
-28.49%
Financial performance
How have Cullinan Oncology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$196.92M
Net income
-$167.38M
Gross margin
N/A
Net margin
N/A
CGEM's net income is down by 17% from the previous quarter and by 9% YoY
The operating income has contracted by 5% from the previous quarter and by 3.1% YoY
Growth
What is Cullinan Oncology's growth rate over time
Valuation
What is Cullinan Oncology stock price valuation
P/E
N/A
P/B
0.86
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 18% since the previous quarter but it is up by 13% year-on-year
The price to book (P/B) is 43% lower than the 5-year quarterly average of 1.5 and 43% lower than the last 4 quarters average of 1.5
Cullinan Oncology's equity has increased by 30% YoY but it has decreased by 6% from the previous quarter
Efficiency
How efficient is Cullinan Oncology business performance
CGEM's return on invested capital is up by 22% year-on-year
The company's return on assets fell by 10% QoQ but it rose by 9% YoY
Cullinan Oncology's return on equity has decreased by 9% QoQ but it has increased by 9% YoY
Dividends
What is CGEM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CGEM.
Financial health
How did Cullinan Oncology financials performed over time
CGEM's quick ratio is down by 45% from the previous quarter and by 22% YoY
The current ratio has declined by 45% since the previous quarter and by 21% year-on-year
The debt is 100% smaller than the equity
CGEM's debt to equity has dropped by 100% year-on-year
The debt has declined by 40% year-on-year and by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.